Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer

QI Ran; NIE Xuyang; LIU Xuting; GAO Shengnan; LIU Guoqiang

doi:10.6039/j.issn.1001-0408.2023.11.16

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer

更新时间：2025-09-27

- Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer
- ZHONGGUO YAOFANG Vol. 34, Issue 11, Pages: 1368-1373(2023)
- 作者机构：
  
  1.河北医科大学第三医院临床药学部，石家庄　050051
  2.河北医科大学第四医院临床药理研究部，石家庄　050011
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.11.16
  CLC： R956;R979.1
- Received：08 November 2022，
  
  Revised：2023-05-14，
  
  Accepted：15 May 2023，
  
  Published：15 June 2023
- 稿件说明：
移动端阅览
齐冉,聂旭阳,刘旭婷,等.斯鲁利单抗联合化疗方案一线治疗广泛期小细胞肺癌的药物经济学评价[J].中国药房,2023,34(11):1368-1373.

QI Ran,NIE Xuyang,LIU Xuting,et al.Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(11):1368-1373.
齐冉,聂旭阳,刘旭婷,等.斯鲁利单抗联合化疗方案一线治疗广泛期小细胞肺癌的药物经济学评价[J].中国药房,2023,34(11):1368-1373. DOI： 10.6039/j.issn.1001-0408.2023.11.16.

QI Ran,NIE Xuyang,LIU Xuting,et al.Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(11):1368-1373. DOI： 10.6039/j.issn.1001-0408.2023.11.16.

摘要

目的

从我国卫生体系角度出发评价斯鲁利单抗联合化疗方案一线治疗广泛期小细胞肺癌（ES-SCLC）的经济性。

方法

基于ASTRUM-005研究和相关文献数据构建分区生存模型，模型模拟时限为10年，循环周期为3周，成本和效用值均采用5%的贴现率进行贴现。以质量调整生命年（QALY）作为模型产出指标并计算增量成本-效果比（ICER），评价斯鲁利单抗联合化疗方案（斯鲁利单抗组）对比单纯化疗方案（单纯化疗组）一线治疗ES-SCLC的经济性。采用单因素敏感性分析和概率敏感性分析验证基础分析结果的稳健性，并针对斯鲁利单抗援助计划进行情境分析。

结果

基础分析结果显示，斯鲁利单抗组相对于单纯化疗组的ICER为758 690.27元/QALY，高于以3倍2022年我国人均国内生产总值（GDP）作为的意愿支付（WTP）阈值。情境分析结果显示，斯鲁利单抗组相对于单纯化疗组的ICER为172 275.74元/QALY，低于上述WTP阈值。单因素敏感性分析结果显示，无进展生存状态效用值、斯鲁利单抗价格等对模型结果影响较大。概率敏感性分析结果显示，不考虑斯鲁利单抗援助计划时，斯鲁利单抗组具有经济性的概率为0；但考虑援助计划时，斯鲁利单抗组具有经济性的概率为100%。

结论

在以3倍2022年我国人均GDP为WTP阈值时，斯鲁利单抗组相对于单纯化疗组不具有经济性；但若将援助计划考虑在内，该结果将发生翻转。

Abstract

OBJECTIVE

To evaluate the economics of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small cell lung cancer （ES-SCLC） from the perspective of health system in China.

METHODS

A partitioned survival model was constructed based on the ASTRUM-005 clinical trial and related literature data， with a model simulation time frame of 10 years and a 3-week cycle， and both cost and utility values were discounted using a 5% discount rate. The quality-adjusted life year （QALY） was used as a model output indicator and the incremental cost-effectiveness ratio （ICER） was calculated to evaluate the economics of serplulimab combined with chemotherapy regimens （serplulimab group） versus chemotherapy alone regimens （chemotherapy alone group） for the first-line treatment of ES-SCLC. One-way sensitivity analysis and probabilistic sensitivity analysis were used to verify the robustness of the results of the base-case analysis and to conduct a scenario analysis for the serplulimab patient assistance program.

RESULTS

The results of the base-case analysis showed that compared with chemotherapy alone group， ICER of serplulimab group was 758 690.27 yuan/QALY， which was higher than 3 times China’s per capita gross domestic product （GDP） in 2022 as the willingness-to-pay （WTP） threshold. The results of the scenario analysis showed that compared with chemotherapy alone group， the ICER of serplulimab group was 172 275.74 yuan/QALY， which was below above WTP threshold. The one-way sensitivity analysis showed that the progress-free survival utility value， serplulimab price and so on had a significant impact on the model results. The results of the probabilistic sensitivity analysis showed that the probability of the serplulimab group being economic was 0 when the serplulimab patient assistance program was not considered， but 100% when the patient assistance program was considered.

CONCLUSIONS

At a WTP threshold of 3 times China’s per capita GDP in 2022， the serplulimab group is no cost-effectiveness compared to the chemotherapy alone group； however， this result is reversed when the patient assistance program is taken into account.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

ZHENG R S ， ZHANG S W ， ZENG H M ， et al . Cancer incidence and mortality in China，2016 [J ] . J Natl Cancer Cent ， 2022 ， 2 （ 1 ）： 1 - 9 .

WANG S C ， TANG J J ， SUN T T ， et al . Survival changes in patients with small cell lung cancer and disparities between different sexes，socioeconomic statuses and ages [J ] . Sci Rep ， 2017 ， 7 （ 1 ）： 1339 .

SIEGEL R L ， MILLER K D ， JEMAL A . Cancer statistics，2015 [J ] . CA ， 2015 ， 65 （ 1 ）： 5 - 29 .

FRÜH M ， DE RUYSSCHER D ， POPAT S ， et al . Small-cell lung cancer （SCLC）：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up [J ] . Ann Oncol ， 2013 ， 24 （ Suppl 6 ）：vi99-vi105.

JONES G S ， ELIMIAN K ， BALDWIN D R ， et al . A systematic review of survival following anti-cancer treatment for small cell lung cancer [J ] . Lung Cancer ， 2020 ， 141 ： 44 - 55 .

SHAO T H ， ZHAO M Y ， LIANG L Y ， et al . Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer：a cost-effectiveness analysis to inform drug pricing [J/OL ] . Bio Drugs ， 2023 [ 2023-05-01 ] . https：//pubmed.ncbi.nlm.nih.gov/36840914/#full-view-affiliation-2 https://pubmed.ncbi.nlm.nih.gov/36840914/#full-view-affiliation-2 . DOI： 10.1007/s40259-023-00586-6 http://dx.doi.org/10.1007/s40259-023-00586-6 .

CHENG Y ， HAN L ， WU L ， et al . Effect of first-line serp- lulimab vs. placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer：the ASTRUM-005 randomized clinical trial [J ] . JAMA ， 2022 ， 328 （ 12 ）： 1223 - 1232 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）小细胞肺癌诊疗指南2022 [M ] . 北京：人民卫生出版社， 2022 ： 17 - 25 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 27 - 46 .

GALLACHER D ， AUGUSTE P ， CONNOCK M . How do pharmaceutical companies model survival of cancer patients? A review of NICE single technology appraisals in 2017 [J ] . Int J Technol Assess Health Care ， 2019 ， 35 （ 2 ）： 160 - 167 .

石丰豪，商叶，芮明军，等 . R语言survHE程序包在卫生经济学评价中的应用 [J ] . 中国卫生经济， 2020 ， 39 （ 9 ）： 9 - 14 .

刘国强，康朔 . 阿替利珠单抗联合标准化疗方案治疗广泛期小细胞肺癌的成本-效用分析 [J ] . 中国药房， 2021 ， 32 （ 1 ）： 77 - 81 .

高红婷，胡梦雪，贾琳琳，等 . 信迪利单抗联合化疗一线治疗晚期或复发性非小细胞肺癌的成本-效用分析 [J ] . 中国药房， 2022 ， 33 （ 15 ）： 1854 - 1859 .

孙蕾，周大创，陈平钰，等 . 恩沙替尼一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学评价 [J ] . 中国药房， 2022 ， 33 （ 12 ）： 1479 - 1484 .

DING D ， HU H ， LI S ， et al . Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer [J ] . J Natl Compr Canc Netw ， 2021 ， 19 （ 10 ）： 1141 - 1147 .

YANG S C ， KUO C W ， LAI W W ， et al . Dynamic changes of health utility in lung cancer patients receiving different treatments：a 7-year follow-up [J ] . J Thorac Oncol ， 2019 ， 14 （ 11 ）： 1892 - 1900 .

ZHU Y ， LIU K ， QIN Q ， et al . Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer：a cost-effectiveness analysis [J ] . Front Immunol ， 2022 ， 13 ： 1044678 .

韩振中，李娜，刘茂柏，等 . 度伐利尤单抗联合化疗一线治疗广泛期小细胞肺癌的成本效果分析 [J ] . 中国新药与临床杂志， 2021 ， 40 （ 5 ）： 373 - 378 .

Views

166

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer

Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma

Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as first-line treatment for HR+/HER2－ metastatic breast cancer

Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC

Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer

Related Author

GAO Ning

GAO Shengnan

ZHANG Yuxi

ZHANG Ranran

FENG Bing

LIU Guoqiang

CHEN Qiuping

SHAO Mingyi

Related Institution

Hebei Provincial Association for Comprehensive Evaluation of Medicines and Health Technologies

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Dept. of Gastroenterology， the First Affiliated Hospital of Henan University of Chinese Medicine

First College of Clinical Medicine， Henan University of Chinese Medicine

Hebei Society for Integrated Drug and Health Technology Assessment

⁰